Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edurne Arriola

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cell Reports. Medicine|June 21, 2025
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancerRaúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Lung cancer patients with COVID-19 in Spain: GRAVID studyMariano Provencio, José María Mazarico Gallego, Antonio Calles, et al.
Oncoimmunology|February 24, 2025
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockadePedro Rocha, Rafael Bach, Laura Masfarré, et al.
JTO Clinical and Research Reports|March 25, 2024
<i>RET</i> Fusion Testing in Patients With NSCLC: The RETING StudyEsther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2025
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trialDolores Isla, Jon Zugazagoitia, Edurne Arriola, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung CancerMelina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING StudyEsther Conde, Susana Hernandez, Rebeca Martinez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cell Reports. Medicine|June 21, 2025
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancerRaúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Lung cancer patients with COVID-19 in Spain: GRAVID studyMariano Provencio, José María Mazarico Gallego, Antonio Calles, et al.
Oncoimmunology|February 24, 2025
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockadePedro Rocha, Rafael Bach, Laura Masfarré, et al.
JTO Clinical and Research Reports|March 25, 2024
<i>RET</i> Fusion Testing in Patients With NSCLC: The RETING StudyEsther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2025
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trialDolores Isla, Jon Zugazagoitia, Edurne Arriola, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung CancerMelina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING StudyEsther Conde, Susana Hernandez, Rebeca Martinez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 9